Piper Jaffray analyst David Amsellem lowered his price target on Sagent Pharmaceuticals (NASDAQ: SGNT) to $32.00 (from $35.00) following Q2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE